Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 13, 2013 (13 years ago)

Ciprofloxacin Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Ciprofloxacin Tablets, USP, 500 mg,100-count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A, NDC 0378-7098-01

Affected NDC 0378-7098-01

Compare with the code on your package — it is the most precise check available.

Drug: Ciprofloxacin Category: Antibiotic

Recalling firm
Mylan Pharmaceuticals Inc.
NDC code
0378-7098-01
Origin
WV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-66403-011 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ciprofloxacin recalls

See all
Class II · Moderate risk

Ciprofloxacin Ophthalmic Solution USP

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 69315-308-05 D-0282-2025
Class II · Moderate risk

Ciprofloxacin Ophth Solution

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect Direct Rx NDC 61919-795-05 D-0364-2025
Class II · Moderate risk

Ciprofloxacin Ophthalmic Solution USP

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 69315-308-05 D-0182-2025
Class II · Moderate risk

Ciprofloxacin ophthalmic solution USP

Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 69315-308-10 D-0623-2024

Other recalls by Mylan Pharmaceuticals Inc.

All 2013 recalls
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026